0001209191-23-001020.txt : 20230104 0001209191-23-001020.hdr.sgml : 20230104 20230104165128 ACCESSION NUMBER: 0001209191-23-001020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221230 FILED AS OF DATE: 20230104 DATE AS OF CHANGE: 20230104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nolan Sean P. CENTRAL INDEX KEY: 0001569926 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 23507398 MAIL ADDRESS: STREET 1: C/O INTERMUNE, INC. STREET 2: 3280 BAYSHORE BLVD. CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-30 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001569926 Nolan Sean P. C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247 1 1 0 0 Chief Executive Officer Stock Option (right to buy) 2.26 2022-12-30 4 A 0 1106131 0.00 A 2032-12-30 Common Stock 1106131 1106131 D 25% of the total number of shares underlying the option shall vest and become exercisable on December 16, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2023-01-04